Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 4/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17860894 | 0.82 | PPARD (0.39) | PPARDCETPLPAR3LPAR1LPAR2 | |
| SCHEMBL2990566 | 0.82 | PPARD (0.39) | PPARDLPAR3LPAR1LPAR2ALDH1A1 | |
| SCHEMBL779021 | 0.81 | LPAR3 (0.48) | PPARDCETPLPAR3LPAR1LPAR2 | |
| SCHEMBL7636250 | 0.81 | PPARD (0.48) | PPARDCETPLPAR3LPAR1LPAR2 | |
| SCHEMBL17878630 | 0.79 | PPARD (0.37) | PPARDCETPLPAR3LPAR1LPAR2 | |
| SCHEMBL28663420 | 0.78 | CETP (0.57) | CETPLPAR3LPAR1LPAR2 | |
| SCHEMBL899361 | 0.78 | PPARD (0.52) | PPARDCETPLPAR3LPAR1LPAR2 | |
| SCHEMBL2992408 | 0.74 | PPARD (0.36) | PPARDLPAR3LPAR1LPAR2ALDH1A1 | |
| SCHEMBL777791 | 0.73 | — | — | |
| SCHEMBL812032 | 0.72 | CYP3A4 (0.56) | PPARDCETPLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| WO-2016100578-A2 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | PPARD 1269/4885CETP 78/4885LPAR3 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.